Cargando…
Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer
Carbohydrate antigen (CA) 19-9 is the only diagnostic marker used in pancreatic cancer despite its limitations. Here, we aimed to identify the diagnostic role of CEMIP (also called KIAA1199) combined with CA 19-9 in patients with pancreatic cancer. A retrospective analysis of prospectively collected...
Autores principales: | Lee, Hee Seung, Jang, Chan Young, Kim, Sun A, Park, Soo Been, Jung, Dawoon E., Kim, Bo Ok, Kim, Ha Yan, Chung, Moon Jae, Park, Jeong Youp, Bang, Seungmin, Park, Seung Woo, Song, Si Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821821/ https://www.ncbi.nlm.nih.gov/pubmed/29467409 http://dx.doi.org/10.1038/s41598-018-21823-x |
Ejemplares similares
-
A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2022) -
Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective study
por: Lee, Hee Seung, et al.
Publicado: (2023) -
Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma
por: Lee, Kyong Joo, et al.
Publicado: (2013) -
Urgent endoscopic retrograde cholangiopancreatography is not superior to early ERCP in acute biliary pancreatitis with biliary obstruction without cholangitis
por: Lee, Hee Seung, et al.
Publicado: (2018) -
Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer
por: Lee, Jeung Eun, et al.
Publicado: (2020)